글로벌 심장판막절삭기 시장 – 2023-2030

Overview
Global cardiac valvulotome market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030. A cardiac valvulotome is a surgical instrument used to cut or incise heart valves during medical procedures such as valvuloplasty and valve replacement surgeries.
Valvulotomy is a surgical procedure that uses a valvulotome to alleviate valve stenosis or regurgitation. This is done by creating controlled incisions in the affected valve leaflets. These incisions can widen narrowed valves and improve their functionality, which helps to restore proper blood flow within the heart. Cardiac surgeons use valvulotomes to treat valve-related diseases and improve cardiac function and patient well-being.
Market Dynamics: Drivers and Restraints
Increasing prevalence of aortic stenosis is expected to drive market growth
The use of a cardiac valvulotome can be beneficial in treating aortic stenosis, which is a condition that causes the aortic valve to narrow and impede the flow of blood from the heart's left ventricle to the rest of the body. When surgical intervention is necessary for severe cases of aortic stenosis, a valvulotomy procedure can be conducted using a valvulotome.

In this medical procedure, precise cuts are made in the thick or fused leaflets of the aortic valve to widen its opening. This improves the flexibility of the valve and reduces pressure on the heart, providing short-term relief from symptoms like chest pain and breathlessness. However, it may not be a permanent solution.

Moreover, the European Society of Cardiology states that Aortic stenosis (AS) is not very common in people under 65 years of age without a congenital abnormality, but its prevalence increases with age. In the United States, it is the second most common valvular lesion. At the age of 65, about 5% of the population has AS and its prevalence increases significantly with age.

In addition, according to recent studies, approximately 12.4% of the population has AS, with 3.4% experiencing severe symptoms among those aged 75 and older. The prevalence of AS increases significantly with age, ranging from 0.2% in the 50-59 age group to 9.8% in those aged 80-89 years. Around 5 in 1,000 individuals experience new cases of AS each year, and this typically occurs in people around the age of 60.

It is common for younger people with clinically significant AS to have bicuspid aortic valve disease, while tricuspid aortic valve stenosis becomes more prevalent in those over 70 years old, often requiring aortic valve replacement. Bicuspid aortic valves are not uncommon, occurring in approximately 0.5-0.8% of the population. In high-income countries, there is an increasing burden of AS, with a significant rise in elderly patients needing treatment (severe symptomatic AS aged 75 years and above) projected by 2050, doubling in both the USA and Europe. Iceland is also expected to have a doubling in the prevalence of severe AS among those aged ≥70 by 2040, with a tripling expected by 2060.

Furthermore, the rising number of cardiac surgeries, including valve repair, and increasing awareness of the importance of early diagnosis and treatment of heart valve conditions are the factors the market is expected to drive the market over the forecast period.
Restraint:
Cardiac valve surgeries and associated procedures are expensive, with potential risks of bleeding, infection, and damage to nearby structures, and the availability of alternatives are the factors expected to hamper the market over the forecast period.

Segment Analysis
The global cardiac valvulotome market is segmented based on product type, surgery type, end user, and region.
The Expandable Cardiac Valvulotome from the Product Type Segment Accounted for Approximately 37.6% of the Cardiac Valvulotome Market Share
Expandable cardiac valvulotomes are becoming more common in modern surgical practice. These devices offer flexibility and adjustability to surgeons and enable the controlled expansion or dilation of valve leaflets. They are precise and versatile, making them suitable for various valve-related procedures like valvuloplasty and valvulotomy. The expandable cardiac valvulotomes are particularly useful in treating valve stenosis and regurgitation.
Moreover, the increasing prevalence of valve diseases, the growing aging population, and advancements in cardiac surgery are the factors expected to drive the market over the forecast period.
For instance, advancements in cardiac surgery have led to the development of more sophisticated and precise instruments, such as Expandable Cardiac Valvulotomes. These tools play a crucial role in transcatheter aortic valve replacement (TAVR) procedures.
TAVR is a less intrusive method of treating aortic valve stenosis, which previously required open-heart surgery. This procedure involves using a catheter to deliver a collapsible artificial valve to the heart, typically through a small incision in the groin or chest.
Before the deployment of a new artificial valve, expandable cardiac valvulotomes are used to either predilate or enlarge the native aortic valve, guaranteeing a secure fit and optimal functionality. The use of instruments like expandable cardiac valvulotomes in TAVR, a minimally invasive procedure, minimizes patient trauma, shortens hospital stays, and speeds up recovery compared to traditional open-heart surgery. This innovation highlights how precise instruments are crucial in modern cardiac surgery, improving patient outcomes, and transforming treatment approaches for valvular heart diseases. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.
Geographical Analysis
North America accounted for approximately 40.3% of the market share in 2022
North America is expected to hold the largest market share owing to the presence of key players, and the increasing prevalence of valvular heart disease.
For instance, according to data from the Centers for Disease Control and Prevention (CDC), Americans suffer from valvular heart disease, and this number tends to increase among older adults. Among the population, approximately 1 in 40 people experience significant valvular heart disease. The mitral and aortic valves are most commonly affected, with around 4 million Americans experiencing significant mitral valve regurgitation. Additionally, roughly 250,000 new cases are diagnosed each year.
The statistics show that many patients require treatment for valvular heart diseases, with the mitral and aortic valves being particularly affected. This widespread occurrence of heart conditions is likely to increase the need for cardiac valvulotomes and other surgical interventions, leading to growth in the cardiac valvulotome market as healthcare providers work to find effective solutions for this common health problem. Hence, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the cardiac valvulotome market by leading to a reduction in the number of cardiac surgeries and valvulotomy procedures performed. For instance, a study was conducted in Lithuania to assess how the COVID-19 pandemic affected a cardiac surgery center's operations. The study revealed that the pandemic had a considerable impact on adult cardiac surgery, resulting in a decline in surgical procedures and a rise in mortality rates. Despite the increased risk of complications in COVID-19-positive patients, the study found that carrying out planned cardiac surgeries with appropriate protective measures during quarantine was a better alternative than completely halting elective cardiac surgeries.
Furthermore, the primary causes of this decrease were the reallocation of healthcare resources to address the surge in COVID-19 cases, the prioritization of critical care, and many patients' reluctance to seek medical attention for non-emergency conditions due to infection concerns. As a result, demand for valvulotomy procedures dropped temporarily, affecting the market. However, as healthcare systems gradually adjusted and resumed elective procedures, the market began to recover, highlighting the resilience of cardiac valvulotome procedures as necessary treatments for valvular heart diseases.
Competitive Landscape
The major global players in the cardiac valvulotome market include LeMaitre Vascular, B. Braun SE, Andramed GmbH, LimFlow, Inc., Teleflex Incorporated, and Symmetry Surgical Inc. among others.
Why Purchase the Report?
• To visualize the global cardiac valvulotome market segmentation based on product type, surgery type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cardiac valvulotome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cardiac valvulotome market report would provide approximately 49 tables, 57 figures, and 170 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies